Efficacy and Safety of Allogeneic Mesenchymal Precursor Cells (Rexlemestrocel-L) for the Treatment of Heart Failure.

The purpose of this study is to evaluate the efficacy and safety of a single transendocardial
delivery in the cardiac catheterization laboratory of human bone marrow-derived allogeneic
MPCs (rexlemestrocel-L) for improvement in clinical outcomes (HF-MACE), preventing further
adverse cardiac remodeling (LVESV and LVEDV), and increasing exercise capacity (6MWT) in
patients with chronic HF due to LV systolic dysfunction of either ischemic or nonischemic
etiology who have received optimal medical/revascularization therapy.

Inclusion Criteria:

- The patient is 18 to 80 years of age, inclusive; both men and women will be enrolled.

- The patient has a diagnosis of chronic HF of ischemic or nonischemic etiology for at
least 6 months

- The patient is on stable, optimally tolerated dosages of HF therapies including
beta-blockers (approved for country-specific usage), angiotensin-converting enzyme
(ACE) inhibitors or angiotensin-receptor blockers (ARBs), and/or aldosterone
antagonists, without change in dose for at least 1 month before study intervention

- The patient is on a stable, outpatient, oral diuretic dosing regimen in which the
patient remains clinically stable during screening.

- Other Criteria apply, please contact the investigator

Exclusion Criteria:

- The patient has NYHA Functional Class I or Functional Class IV symptoms.

- Other Criteria apply, please contact the investigator